Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846424 | 0.81 | ALDH1A1 (0.60) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL10336241 | 0.80 | ALDH1A1 (0.68) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL1806582 | 0.79 | ALDH1A1 (0.56) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL4848399 | 0.78 | SMN1; SMN2 (0.51) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL4850036 | 0.77 | ALDH1A1 (0.51) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL30818053 | 0.75 | MGAM (0.51) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL4843130 | 0.74 | SMN1; SMN2 (0.51) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL189243 | 0.72 | PIK3CD (0.54) | PDPK1ALDH1A1CYP3A4TDP1LMNA | |
| SCHEMBL12641874 | 0.71 | MMP9 (0.49) | ALDH1A1CYP3A4TDP1LMNASMN1; SMN2 | |
| SCHEMBL21989735 | 0.70 | LMNA (0.57) | PDPK1ALDH1A1CYP3A4TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1670794-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005033105-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDPK1 2042/4885ALDH1A1 3253/4885CYP3A4 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.